{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:13:33Z","timestamp":1770905613447,"version":"3.50.1"},"reference-count":10,"publisher":"PAGEPress Publications","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Reports"],"abstract":"<jats:p>Dear Editor,\nSystemic sclerosis (SSc) is an autoimmune connective tissue disease mainly characterized by endothelial dysfunction, aberrant immune activation, and excessive extracellular matrix deposition affecting the skin and visceral organs. SSc exhibits marked clinical heterogeneity, with an estimated prevalence of 7.2-44.3 per 100,000 individuals and a strong female predominance (female-to-male ratio 3:1-8:1). Based on the extent of cutaneous involvement, SSc is classified into limited and diffuse forms. The limited subtype typically progresses slowly and affects distal acral areas, whereas the diffuse form is characterized by rapid, widespread proximal and truncal involvement with early internal organ fibrosis. [...]<\/jats:p>","DOI":"10.4081\/dr.2026.10652","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:22:30Z","timestamp":1770902550000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful use of upadacitinib for the improvement of vitiligo-like and perifollicular dyspigmentation (salt-and-pepper skin) in systemic sclerosis"],"prefix":"10.4081","author":[{"given":"Giovanni","family":"Paolino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo Riccardo","family":"Di Nicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santo Raffaele","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Canti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2549","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"36428","doi-asserted-by":"crossref","unstructured":"1. Kridin K, Lyakhovitsky K, Tzur\u2010Bitan D, et al. Vitiligo and systemic sclerosis: Are they associated?\u2013 Lessons from a population\u2010based study. Aust J Dermatol 2023;64:e65-71.","DOI":"10.1111\/ajd.13942"},{"key":"36429","doi-asserted-by":"crossref","unstructured":"2. Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol 2018;32:223-40.","DOI":"10.1016\/j.berh.2018.08.005"},{"key":"36430","doi-asserted-by":"crossref","unstructured":"3. Kitchen H, Wyrwich KW, Carmichael C, et al. Meaningful Changes in What Matters to Individuals with Vitiligo: Content Validity and Meaningful Change Thresholds of the Vitiligo Area Scoring Index (VASI). Dermatol Ther (Heidelb) 2022;12:1623-37.","DOI":"10.1007\/s13555-022-00752-8"},{"key":"36431","doi-asserted-by":"crossref","unstructured":"4. Sarfaraz S, Chang J, Kirchhof MG. Upadacitinib as a potential management option for diffuse cutaneous systemic sclerosis: A case report. SAGE Open Med Case Rep 2025;13:2050313X251343300.","DOI":"10.1177\/2050313X251343300"},{"key":"36432","doi-asserted-by":"crossref","unstructured":"5. Moriana C, Moulinet T, Jaussaud R, Decker P. JAK inhibitors and systemic sclerosis: A systematic review of the literature. Autoimmun Rev 2022;21:103168.","DOI":"10.1016\/j.autrev.2022.103168"},{"key":"36433","doi-asserted-by":"crossref","unstructured":"6. Fiorentini E, Bonomi F, Peretti S, et al. Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data. Life 2022;12:2101.","DOI":"10.3390\/life12122101"},{"key":"36434","doi-asserted-by":"crossref","unstructured":"7. McGaugh S, Kallis P, De Benedetto A, Thomas RM. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review. Dermatol Ther 2022;35:15437.","DOI":"10.1111\/dth.15437"},{"key":"36435","doi-asserted-by":"crossref","unstructured":"8. Passeron T, Ezzedine K, Hamzavi I, et al. Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study. eClinicalMedicine 2024;73:102655.","DOI":"10.1016\/j.eclinm.2024.102655"},{"key":"36436","doi-asserted-by":"crossref","unstructured":"9. Mittal S, Khaitan BK, Ramam M, et al. Pigmentary Changes in Systemic Sclerosis are Associated with More Severe Cutaneous Sclerosis and Severity of Other Systems: A Cross-sectional Study from India. Indian J Dermatol 2024;69:365.","DOI":"10.4103\/ijd.ijd_251_24"},{"key":"36437","doi-asserted-by":"crossref","unstructured":"10. Romanowska-Pr\u00f3chnicka K, Dziewit M, Lesiak A, et al. Scleroderma and scleroderma-like syndromes. Front Immunol 2024;15:1351675.","DOI":"10.3389\/fimmu.2024.1351675"}],"container-title":["Dermatology Reports"],"original-title":[],"link":[{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10652\/9867","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/download\/10652\/9867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:22:40Z","timestamp":1770902560000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.pagepress.net\/dr\/article\/view\/10652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":10,"URL":"https:\/\/doi.org\/10.4081\/dr.2026.10652","relation":{},"ISSN":["2036-7406","2036-7392"],"issn-type":[{"value":"2036-7406","type":"electronic"},{"value":"2036-7392","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,12]]}}}